Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Lung Neoplasms D008175 171 associated lipids
Adenocarcinoma D000230 166 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Edema D004487 152 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hemolysis D006461 131 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Inflammation D007249 119 associated lipids
Hypertension D006973 115 associated lipids
Glioma D005910 112 associated lipids
Weight Gain D015430 101 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Brain Ischemia D002545 89 associated lipids
Seizures D012640 87 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Arteriosclerosis D001161 86 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Atherosclerosis D050197 85 associated lipids
Stomach Ulcer D013276 75 associated lipids
Hyperlipidemias D006949 73 associated lipids
Carcinoma, Non-Small-Cell Lung D002289 72 associated lipids
Coronary Disease D003327 70 associated lipids
Colitis D003092 69 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Reperfusion Injury D015427 65 associated lipids
Pain D010146 64 associated lipids
Weight Loss D015431 56 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Asthma D001249 52 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Thrombosis D013927 49 associated lipids
Fatty Liver D005234 48 associated lipids
Coronary Artery Disease D003324 47 associated lipids
Metabolic Syndrome D024821 44 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Hyperalgesia D006930 42 associated lipids
Hypotension D007022 41 associated lipids
Arthritis D001168 41 associated lipids
Diabetic Retinopathy D003930 39 associated lipids
Zellweger Syndrome D015211 39 associated lipids
Diabetic Nephropathies D003928 39 associated lipids
Lung Diseases D008171 37 associated lipids
Liver Cirrhosis, Experimental D008106 36 associated lipids
Heart Failure D006333 36 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Ushiyama S et al. RS-5186, a novel thromboxane synthetase inhibitor with a potent and extended duration of action. 1988 Thromb. Res. pmid:3175990
Kosaki G et al. The mechanism of the inhibitory effect of protease inhibitors on platelet aggregation and cellular synthesis of prostaglandins. I. The effect on the release of arachidonic acid from phospholipids. 1980 Dec 1-15 Thromb. Res. pmid:6785893
Rostagno C et al. In vitro effects of two novel calcium antagonists (nitrendipine and nisoldipine) on intraplatelet calcium redistribution, platelet aggregation and thromboxane A2 formation. Comparison with diltiazem, nifedipine and verapamil. 1991 Thromb. Res. pmid:1754998
Catella F and FitzGerald GA Paired analysis of urinary thromboxane B2 metabolites in humans. 1987 Thromb. Res. pmid:3686481
Kohda N et al. Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery. 1999 Thromb. Res. pmid:10593428
Winther K et al. Platelet function and fibrinolytic activity in cervical spinal cord injured patients. 1992 Thromb. Res. pmid:1321515
Davì G et al. Inhibition of platelet function by ticlopidine in arteriosclerosis obliterans of the lower limbs. 1985 Thromb. Res. pmid:2933846
Takasaki W et al. Enzyme immunoassay of human plasma 11-dehydrothromboxane B2. 1991 Thromb. Res. pmid:1957275
Pirich C et al. Effects of fish oil supplementation on platelet survival and ex vivo platelet function in hypercholesterolemic patients. 1999 Thromb. Res. pmid:10588465
Altman R et al. Synergistic actions of PAF-acether and sodium arachidonate in human platelet aggregation. 1. Studies in normal human platelet rich plasma. 1986 Thromb. Res. pmid:3014677
Yamaguchi A et al. Effect of cetiedil on platelet aggregation and thromboxane synthesis. 1985 Thromb. Res. pmid:2986312
Lukaszyk A et al. Does acute experimental pancreatitis affect blood platelet function? 1989 Thromb. Res. pmid:2524119
Swart SS et al. Functional significance of the platelet alpha2-adrenoceptor: studies in patients with myeloproliferative disorders. 1984 Thromb. Res. pmid:6326344
Alessandrini P et al. Physiologic variables affecting thromboxane B2 production in human whole blood. 1985 Thromb. Res. pmid:3983893
Best LC et al. The interrelationship between thromboxane biosynthesis, aggregation and 5-hydroxytryptamine secretion in human platelets in vitro. 1980 Thromb. Haemost. pmid:6773171
Han P et al. Inhibition of platelet function of antiarrhythmic drugs, verapamil and disopyramide. 1982 Thromb. Haemost. pmid:7101234
Greer IA et al. A comparative study of the effects of adrenoceptor antagonists on platelet aggregation and thromboxane generation. 1985 Thromb. Haemost. pmid:2867620
Miller KW and Keith JC Effect of thromboxane synthetase inhibition on platelet function and morphology during ovine pregnancy-induced hypertension. 1988 Thromb. Haemost. pmid:3238644
Teng CM et al. ADP-mimicking platelet aggregation caused by rugosin E, an ellagitannin isolated from Rosa rugosa Thunb. 1997 Thromb. Haemost. pmid:9066010
Joseph S et al. Effect of the polyamine-spermine on agonist-induced human platelet activation--specific inhibition of "aggregation-independent" events induced by thrombin, but not by collagen, thromboxane mimetic, phorbol ester or calcium ionophore. 1987 Thromb. Haemost. pmid:3110996
di Minno G et al. Effects of any epoxymethano stable analogue of prostaglandin endoperoxides (U-46619) on human platelets. 1981 Thromb. Haemost. pmid:6266066
Pampolina C and McNicol A Streptococcus sanguis-induced platelet activation involves two waves of tyrosine phosphorylation mediated by FcgammaRIIA and alphaIIbbeta3. 2005 Thromb. Haemost. pmid:15886812
Jilma-Stohlawetz P et al. Impaired platelet function among platelet donors. 2001 Thromb. Haemost. pmid:11583322
Dejana E et al. Bleeding time in rats: a comparison of different experimental conditions. 1982 Thromb. Haemost. pmid:6753230
Strano A et al. Platelet sensitivity to prostacyclin and thromboxane production in hyperlipidemic patients. 1982 Thromb. Haemost. pmid:6753232
Swartz SL and Moore TJ Effect of angiotensin II on collagen-induced platelet activation in normotensive subjects. 1990 Thromb. Haemost. pmid:2339363
Siess W et al. Stimulated platelet aggregation, thromboxane B2 formation and platelet sensitivity to prostacyclin - a critical evaluation. 1981 Thromb. Haemost. pmid:7025338
Watanabe J et al. Effect of vitamin E on platelet aggregation in diabetes mellitus. 1984 Thromb. Haemost. pmid:6495252
Carter AJ et al. A comparison of human pulmonary arterial and venous prostacyclin and thromboxane synthesis--effect of a thromboxane synthase inhibitor. 1984 Thromb. Haemost. pmid:6377567
Spectre G et al. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. 2011 Thromb. Haemost. pmid:21800009
Kyrle PA et al. Investigation of the interaction of blood platelets with the coagulation system at the site of plug formation in vivo in man--effect of low-dose aspirin. 1987 Thromb. Haemost. pmid:2954260
Gresele P et al. Picotamide protects mice from death in a pulmonary embolism model by a mechanism independent from thromboxane suppression. 1990 Thromb. Haemost. pmid:2274931
Krishnamurthi S et al. Effect of pyridoxal 5'-phosphate (PALP) on human platelet aggregation, dense granule release and thromboxane B2 generation--role of Schiff base formation. 1982 Thromb. Haemost. pmid:6891107
Essien EM et al. Blood changes and enhanced thromboxane and 6-keto prostaglandin F1 alpha production in experimental acute Plasmodium bergei infection in hamsters. 1984 Thromb. Haemost. pmid:6388013
Chen SL et al. Chlorobutanol, a preservative of desmopressin, inhibits human platelet aggregation and release in vitro. 1990 Thromb. Haemost. pmid:2096493
Martinuzzo ME et al. Antiphospholipid antibodies enhance thrombin-induced platelet activation and thromboxane formation. 1993 Thromb. Haemost. pmid:8115993
Stratta P et al. Warning: platelet factor 4, beta-thromboglobulin and thromboxane in donor's plasma units. 1983 Thromb. Haemost. pmid:6189235
Larson MK et al. Effects of omega-3 acid ethyl esters and aspirin, alone and in combination, on platelet function in healthy subjects. 2008 Thromb. Haemost. pmid:18841286
Hoet B et al. Ridogrel, a combined thromboxane synthase inhibitor and receptor blocker, decreases elevated plasma beta-thromboglobulin levels in patients with documented peripheral arterial disease. 1990 Thromb. Haemost. pmid:2148849
Cattaneo M et al. Human platelet aggregation and release reaction induced by platelet activating factor (PAF-acether)--effects of acetylsalicylic acid and external ionized calcium. 1985 Thromb. Haemost. pmid:3927505
Wang WJ and Huang TF A novel tetrameric venom protein, agglucetin from Agkistrodon acutus, acts as a glycoprotein Ib agonist. 2001 Thromb. Haemost. pmid:11686327
Davì G et al. Increased thromboxane metabolites excretion in liver cirrhosis. 1998 Thromb. Haemost. pmid:9569186
Sheu JR et al. Mechanisms involved in the antiplatelet activity of Staphylococcus aureus lipoteichoic acid in human platelets. 2000 Thromb. Haemost. pmid:10823277
Crescente M et al. Gallic acid, a dietary polyphenolic component, blunts the inhibition of platelet COX-1 by aspirin: preliminary in-vitro findings. 2007 Thromb. Haemost. pmid:17549313
Landolfi R et al. Effects of unfractionated and low molecular weight heparins on platelet thromboxane biosynthesis "in vivo". 1994 Thromb. Haemost. pmid:7740468
Undas A et al. Lack of aspirin-induced decrease in thrombin formation in subjects resistant to aspirin. 2007 Thromb. Haemost. pmid:17549314
Homoncik M et al. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. 2000 Thromb. Haemost. pmid:10739392
Perneby C et al. Dose- and time-dependent antiplatelet effects of aspirin. 2006 Thromb. Haemost. pmid:16601836
Eldor A et al. Effects of dipyrone on prostaglandin production by human platelets and cultured bovine aortic endothelial cells. 1983 Thromb. Haemost. pmid:6346571
Menys VC and Davies JA Selective inhibition of thromboxane synthetase with dazoxiben - basis of its inhibitory effect on platelet adhesion. 1983 Thromb. Haemost. pmid:6346575
Hampton KK et al. Coagulation, fibrinolytic and platelet function in patients on long-term therapy with aspirin 300 mg or 1,200 mg daily compared with placebo. 1990 Thromb. Haemost. pmid:2073296
Vejar M et al. Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina. 1990 Thromb. Haemost. pmid:2363117
Foo LC et al. Platelets of habitual smokers have reduced susceptibility to aggregating agent. 1991 Thromb. Haemost. pmid:2048056
Dragani A et al. Oxidative stress and platelet activation in subjects with moderate hyperhomocysteinaemia due to MTHFR 677 C→T polymorphism. 2012 Thromb. Haemost. pmid:22782530
Gordge MP et al. Platelet function and the bleeding time in progressive renal failure. 1988 Thromb. Haemost. pmid:3187950
D'Angelo A et al. Effect of des-amino-D-arginine vasopressin (DDAVP) on plasma levels of platelet and endothelial cell release products. 1983 Thromb. Haemost. pmid:6687766
Lessiani G et al. Inflammation, oxidative stress and platelet activation in aspirin-treated critical limb ischaemia: beneficial effects of iloprost. 2011 Thromb. Haemost. pmid:21103664
Hohlfeld T et al. Antiplatelet effects of ticlopidine are reduced in experimental hypercholesterolemia. 1994 Thromb. Haemost. pmid:7513092
Guthikonda S et al. Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy. 2008 Thromb. Haemost. pmid:18612542
Naesh O et al. Platelet function in surgical stress. 1985 Thromb. Haemost. pmid:2935969
Michelson AD et al. Reversible inhibition of human platelet activation by hypothermia in vivo and in vitro. 1994 Thromb. Haemost. pmid:7522354
Dale J et al. The effect of a thromboxane synthetase inhibitor, dazoxiben, and acetylsalicylic acid on platelet function and prostaglandin metabolism. 1983 Thromb. Haemost. pmid:6689091
Hornby EJ et al. The inhibitory effect of GR32191, a thromboxane receptor blocking drug, on human platelet aggregation, adhesion and secretion. 1989 Thromb. Haemost. pmid:2529661
Bar J et al. The regulation of platelet aggregation in vitro by interleukin-1beta and tumor necrosis factor-alpha: changes in pregnancy and in pre-eclampsia. 1997 Thromb. Haemost. pmid:9364994
Husted SE et al. Intravenous acetylsalicylic acid--dose-related effects on platelet function and fibrinolysis in healthy males. 1992 Thromb. Haemost. pmid:1412171
Wang JS et al. Effect of strenuous arm exercise on oxidized-LDL-potentiated platelet activation in individuals with spinal cord injury. 2000 Thromb. Haemost. pmid:10928481
Barrett PA and Butler KD Shortening of platelet survival by induced hypercholesterolaemia in rabbits and its prolongation by anagrelide. 1983 Thromb. Haemost. pmid:6648889
Halawani SH et al. Aspirin failure in patients presenting with acute cerebrovascular ischaemia. 2011 Thromb. Haemost. pmid:21544317
Connellan JM et al. Investigation of alternative mechanisms of collagen-induced platelet activation by using monoclonal antibodies to glycoprotein IIb-IIIa and fibrinogen. 1986 Thromb. Haemost. pmid:2940722
Patrono C et al. Characterization of biochemical and functional effects of antiplatelet drugs as a key to their clinical development. 1995 Thromb. Haemost. pmid:8578493
Cortellaro M et al. Transcoronary platelet thromboxane A2 formation without platelet trapping in patients with coronary stenosis-effect of sulphinpyrazone treatment. 1983 Thromb. Haemost. pmid:6665767
Szczeklik A et al. Prolonged bleeding time, reduced platelet aggregation, altered PAF-acether sensitivity and increased platelet mass are a trait of asthma and hay fever. 1986 Thromb. Haemost. pmid:3563961
Larsen SB et al. Increased platelet aggregation and serum thromboxane levels in aspirin-treated patients with prior myocardial infarction. 2012 Thromb. Haemost. pmid:22534977
Fruzzetti F et al. Platelet-vessel wall interactions with third-generation oral contraceptives: no evidence of detrimental effects. 1999 Thromb. Haemost. pmid:10494782
Cattaneo M et al. Conditions influencing the interaction of asialo von Willebrand factor with human platelets--the effects of external ionized calcium concentration and the role of arachidonate pathway. 1988 Thromb. Haemost. pmid:3146144
Fimognari FL et al. Nocturnal rise of urinary thromboxane B 2 in patients with coronary artery disease. 2005 Thromb. Haemost. pmid:15735822
De Caterina R et al. Organic nitrates: direct antiplatelet effects and synergism with prostacyclin. Antiplatelet effects of organic nitrates. 1988 Thromb. Haemost. pmid:3291182
Teng CM and Ko FN Comparison of the platelet aggregation induced by three thrombin-like enzymes of snake venoms and thrombin. 1988 Thromb. Haemost. pmid:3291184
de Castellarnau C et al. Prostacyclin and thromboxane production by autogenous femoral veins grafted into the arterial circulation of the dog. 1989 Thromb. Haemost. pmid:2665174
Zahavi J and Zahavi M Enhanced platelet release reaction, shortened platelet survival time and increased platelet aggregation and plasma thromboxane B2 in chronic obstructive arterial disease. 1985 Thromb. Haemost. pmid:3158092
Etulain J et al. Acidosis downregulates platelet haemostatic functions and promotes neutrophil proinflammatory responses mediated by platelets. 2012 Thromb. Haemost. pmid:22159527
Rocca B et al. Increased thromboxane biosynthesis in essential thrombocythemia. 1995 Thromb. Haemost. pmid:8607099
Pettinella C et al. Cyclooxygenase-1 haplotype C50T/A-842G does not affect platelet response to aspirin. 2009 Thromb. Haemost. pmid:19350112
Totani L et al. Prasugrel inhibits platelet-leukocyte interaction and reduces inflammatory markers in a model of endotoxic shock in the mouse. 2012 Thromb. Haemost. pmid:22436970
Véricel E et al. Moderate oral supplementation with docosahexaenoic acid improves platelet function and oxidative stress in type 2 diabetic patients. 2015 Thromb. Haemost. pmid:25832443
Kyrle PA et al. Evidence for an increased generation of prostacyclin in the microvasculature and an impairment of the platelet alpha-granule release in chronic renal failure. 1988 Thromb. Haemost. pmid:2975407
Spowart K et al. Haemostatic effects of ketorolac with and without concomitant heparin in normal volunteers. 1988 Thromb. Haemost. pmid:3266379
Cerletti C et al. Aspirin kinetics and inhibition of platelet thromboxane generation-relevance for a solution of the "aspirin dilemma". 1985 Thromb. Haemost. pmid:4049312
Hillbom M et al. Platelet thromboxane formation and bleeding time is influenced by ethanol withdrawal but not by cigarette smoking. 1985 Thromb. Haemost. pmid:4049313
Aoki T et al. Difference of (Ca2+)i movements in platelets stimulated by thrombin and TRAP: the involvement of alpha(IIb)beta3-mediated TXA2 synthesis. 1998 Thromb. Haemost. pmid:9657446
McMahon GS et al. Transient heparin-induced platelet activation linked to generation of platelet 12-lipoxygenase. Findings from a randomised controlled trial. 2013 Thromb. Haemost. pmid:23494053
Dotevall A et al. Cigarette smoking increases thromboxane A2 formation without affecting platelet survival in young healthy females. 1992 Thromb. Haemost. pmid:1455405
De Caterina R et al. Benefit/risk profile of combined antiplatelet therapy with ticlopidine and aspirin. 1991 Thromb. Haemost. pmid:1871711
de Boer A et al. Interaction study between Org 10172, a low molecular weight heparinoid, and acetylsalicylic acid in healthy male volunteers. 1991 Thromb. Haemost. pmid:1722918
Blais N et al. Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2). 2009 Thromb. Haemost. pmid:19652893
Forastiero R et al. Anti-beta2 glycoprotein I antibodies and platelet activation in patients with antiphospholipid antibodies: association with increased excretion of platelet-derived thromboxane urinary metabolites. 1998 Thromb. Haemost. pmid:9459320
Holme S et al. The effect of albumin bound polyunsaturated fatty acids on human platelets. 1984 Thromb. Haemost. pmid:6719386
Carter AJ and Hanley SP The effect of platelet number and haematocrit on whole blood thromboxane synthesis. 1985 Thromb. Haemost. pmid:4024033
Brox JH et al. The effect of cod liver oil and corn oil on platelets and vessel wall in man. 1981 Thromb. Haemost. pmid:7031981
Strano A et al. Thromboxane formation by platelets and platelet sensitivity to prostacyclin in patients with acute myocardial infarction. 1981 Thromb. Haemost. pmid:7036402